Diligence memo · auto-generated · as of July 2, 2026
Optikira, LLC
Optikira, LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Optikira, LLC operates in Pharmaceuticals, based in CLEVELAND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Optikira, LLC has raised $8.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.1M on 2014-11-30.
Most recent recorded round closed around 2018-05-25.
Valuation (modeled)modeled
Provath models Optikira, LLC at approximately $84M (range $3.1M–$455M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.47× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 8.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 52% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.